Navigation Links
Varian, Inc. Acquires Oxford Diffraction, Ltd.
Date:4/6/2008

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) announced today that it has acquired Oxford Diffraction, Ltd., a privately owned company based in Abingdon, U.K. Oxford Diffraction is a leader in x-ray crystallography, an analytical technique used by scientists in pharmaceutical research and other research laboratories to determine the structure of both small molecules and large molecules such as proteins.

For crystalline compounds, x-ray crystallography is the most powerful technique available for structural analysis. Nuclear magnetic resonance (NMR) provides complementary structural information for compounds in the solid state and also structural information for compounds in solutions.

"The acquisition of Oxford Diffraction is key to Varian's goal of broadening its range of information-rich detection products for life science research," said Garry W. Rogerson, President and CEO, Varian, Inc. "Oxford Diffraction has experienced rapid growth since its formation in 2001 and has established a strong reputation in single crystal X-ray crystallography, particularly in Europe. Oxford Diffraction products will now be distributed on a global basis via Varian's worldwide distribution network."

"In addition to the obvious benefit to our business of a much larger distribution and support organization, the sale of Oxford Diffraction to Varian brings a number of additional important advantages," said Paul Loeffen CEO of Oxford Diffraction. "We now have the opportunity to offer customers more powerful solutions through combinations of complementary information-rich techniques to include X-ray crystallography, nuclear magnetic resonance (NMR) spectrometry and liquid chromatography-mass spectrometry (LC-MS). Furthermore, as part of Varian, we look forward to continuing the development of innovative technologies and products for our customers."

"Existing Oxford Diffraction customers will continue to benefit
'/>"/>

SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
2. Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides.
3. Varian, Inc. Acquires Analogix Business
4. Varian, Inc. CEO to Speak at JPMorgan Healthcare Conference
5. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
6. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
7. New Ion Trap Mass Spectrometers From Varian, Inc. Offer the Ultimate in Sensitive Detection and High Productivity
8. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
9. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
10. Food Bank For New York City Acquires FoodChange
11. Concentra Acquires Assets of Renew Health & Wellness

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... ONDAMED® praised by Suzanne Somers in her N.Y... Cornwall, NY (PRWEB) December 2, 2009 --... Who Are Curing Cancer, And How to Prevent Getting...doctors who are successfully using the most innova...he body rather than tear it down. This is a subjec...
(Date:12/2/2009)... Leading medical device software engineering consu... 13485 certification. A relatively few medical dev...ually achieved ISO 13485 certification. Many medic...adhere to other ISO standards as well. However, it...gineering consulting firm to achieve the rigorous ...
(Date:12/2/2009)... 2 Targeted breast ultr...g lumps, is a safe, reliable and cost-effective al... 40, according to the findings of two studies pres...cal Society of North America (RSNA). ,, "By per...uce the number of expensive and avoidable invasive...
(Date:12/2/2009)...arge-scale clinical trial presented today at the a... America (RSNA) provide the first strong evidence ...women with dense breasts who are at elevated risk ...d that MRI is highly sensitive in depicting early ... with ultrasound in addition to mammography signif...
(Date:12/1/2009)...K, Dec. 1 Reportlinker.com announc...in its catalogue: ,, Emerging Clinical Trial ...g healthcare and regulatory environment ,, h...cal-Trial-Locations---India-Market-dynamics-and-th...tml ,, Over the last decade pharmaceutical and...
Breaking Medicine News(10 mins):Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 7
...ovember issue of Developmental Psychology has expl...picture-book reading with their children, // which...them to the world outside. This is thought to be h... and spend approximately 40 minutes a day reading ...
...la will soon head for the Maldives to care for pat...s from Kerala are to leave for the Maldives courte... Promotion Consultants (ODEPC). 'The first b.... 'The Maldives has also asked us to recruit...
...d? Yes, within the brain, say researchers. Brain ...essing mechanism has never been easy. //Meditators...ntly chattering. Researchers have come up with a f...n you least expect it. We often experience that th...
...ual health campaign is targeting young adults to c...r focus is mainly on 18 to 24-year-olds. //Current...ed to carry condoms on a night out. The ?4m ca...ealth groups but pointed out that a further ?46m h...
...captured the imagination of the world as a 'repeto...joled into restoring or rejuvenating debilitating ...ientists have helped to reiterate this belief, by ... could be lauded as a 'mile stone' in stem cell re...
...opular world over for its quality poultry products...ed to a record 3.26 Billion Rupees. //However the ...rldwide epidemic brought the poultry revenues cras...Influenza' has been known to affect humans though ...
Other Medicine News:Health News:Picture Book Reading Helps Toddlers Grasp Complex Actions 2Health News:Noise In Neurons Is good 2Health News:Risk-Taking Young Urged To Carry Condoms 2Health News:Research 'Extraordinaire' To Restore Vision 2Health News:India Free From Bird Flu 2
(Date:12/1/2009)...., Dec. 1 CeloNova BioSciences, In... medical devices and of specialty implants, today ..., founder and medical director of Baptist Cardiac ...iscuss the CATANIA(TM) Stent System with NanoThin ...lar Interventions Conference to be held at the Hot...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
(Date:12/1/2009)...., Dec. 1 SCOLR Pharma, ... 20, 2009 it licensed to Chrono Nutraceuticals LLC...l four extended release dietary supplements using ...rm. In addition, SCOLR granted Chrono rights to m...ited States on a nonexclusive basis. Chrono paid ...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3American Nurses Association Joins the National Healthcare Career Network 54285 1American Nurses Association Joins the National Healthcare Career Network 54285 2American Nurses Association Joins the National Healthcare Career Network 54285 3Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 1Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 2Scientist Verifies That The Ancient Practice Of Girding The Loins Increases Health 54281 3The tourist trap 9540 1
...ial New Front-Line Treatment ...Genzyme Corp.,(Nasdaq: GENZ ) reported preliminar...2 study examining the safety and effectiveness of ...ously untreated, older adult,patients with acute m...fit,from conventional "7+3" anthracycline plus cyt...
...CALS, INC. (Nasdaq: VION ) today announced that i... lead anticancer agent Cloretazine(R),(VNP40101M) ...yelogenous,leukemia (AML) had been presented at th...linical Oncology (ASCO(R)) in Chicago, Illinois., ...atients. The median,age of these patients was 73 y...
Other Medicine Technology:Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4
Fast-Cath™ Guiding Introducers
Lumenis 1000 Integrated Slit Lamp
Novus 30001
Selecta Trio Photocoagulator and SLT Combination Laser
Medicine Products: